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Abstract 
Compared with subcutaneous or intramuscular routes for vaccination, vaccine delivery via 
gastrointestinal mucosa has tremendous potential as it is easy to administer and pain free. Robust 
immune responses can be triggered successfully once vaccine carried antigen reaches the mucosal 
associated lymphoid sites (e.g., Peyer’s patches). However, the absence of an efficient delivery method 
has always been an issue for successful oral vaccine development. In our study, inspired by mammalian 
orthoreovirus (MRV) transport into gut mucosal lymphoid tissue via Microfold cells (M cells), artificial 
virus-like nanocarriers (AVN), consisting of gold nanocages functionalized with the 1 protein from 
mammalian reovirus (MRV), were tested as an effective oral vaccine delivery vehicle targeting M cells. 
AVN was shown to have a significantly higher transport compared to other experimental groups across 
mouse organoid monolayers containing M cells. These findings suggest that AVN has the potential to be 
an M cell-specific oral vaccine/drug delivery vehicle. 
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1 Transport of Artificial Virus-like Nanocarriers (AVN) through 
2 intestinal monolayer via Microfold cells    
3
4 Tianjian Tong§, Yijun Qi§, Luke D. Bussiere, Michael Wannemuehler, Cathy L. Miller, Qun Wang*, Chenxu 
5 Yu*
6 Compared with subcutaneous or intramuscular routes for vaccination, vaccine delivery via 
7 gastrointestinal mucosa has tremendous potential as it is easy to administer and pain free. Robust 
8 immune responses can be triggered successfully once vaccine carried antigen reaches the mucosal 
9 associated lymphoid sites (e.g., Peyer’s patches). However, the absence of an efficient delivery 
10 method has always been an issue for successful oral vaccine development. In our study, inspired by 
11 mammalian orthoreovirus (MRV) transport into gut mucosal lymphoid tissue via Microfold cells (M 
12 cells), artificial virus-like nanocarriers (AVN), consisting of gold nanocages functionalized with the 1 
13 protein from mammalian reovirus (MRV), were tested as an effective oral vaccine delivery vehicle 
14 targeting M cells. AVN was shown to have a significantly higher transport compared to other 
15 experimental groups across mouse organoid monolayers containing M cells. These findings suggest 
16 that AVN has the potential to be an M cell-specific oral vaccine/drug delivery vehicle.
17 Introduction
18 Oral vaccination targeting the gastrointestinal (GI) mucosa layer is considered more patient-friendly to 
19 subcutaneous injection or intravenous injection with regards to induction of a protective immune 
20 response1. GI mucosal delivery of vaccines has additional practical advantages over vaccination by 
21 intravenous injection or subcutaneous injection, including both cost efficiency and increased safety 2. 
22 While progress has been made substantially with the increased stability of and immune activation by 
23 mucosal vaccines, practical and effective oral vaccine delivery systems targeting GI mucosa remain to be 
24 developed due to poor understanding of specific and non-specific factors determining delivery, 
25 targeting, recognition and transport of vaccine/vaccine carriers across the GI mucosal epithelia. In this 
26 article, we aimed to validate the development of an artificial virus-like nanocarrier which specifically 
27 targets M cells for transcytosis providing a more effective strategy to deliver oral vaccines into mucosal 
28 associated lymphoid tissues (e.g., Peyer’s patches) for enhanced vaccine efficacy.
29 Type 1 Lang mammalian reovirus (MRV) is an 85 nm diameter, non-enveloped virus comprised of 5 
30 structural proteins (λ1, λ2, λ3, σ2, and μ2) forming a core particle that encloses the virus genome, 
31 surrounded by 3 outer capsid proteins (σ1, μ1, and σ3) that play critical roles in virus cell entry3. 
32 Following oral inoculation, T1L MRV accesses mucosal associated lymphoid tissue (MALT) by transcytosis 
33 through M cells, which are specialized cells located at follicle-associated epithelium (FAE ) of Peyer’s 
34 patches4,5. M cells are continuously sampling for foreign antigens within the lumen by endocytosing 
35 antigens suspended in fluid at the apical surface of the cell. These antigens are then transcytosed from 
36 the apical surface to the basolateral surface. Since there is a thick mucus layer on the apical surface of 
37 the enterocytes, viruses often exploit M cell sampling to gain access to the basolateral side of the 
38 enterocytes where infection can proceed. In the case of MRV, the MRV outer capsid protein, σ1, 
39 adheres to 2-3-linked sialic acids on the M cell apical surface, then the T1L MRV is transcytosed across 
40 the M cell to the to MALT where it can initiate infection of enterocytes on the basolateral surface of 
41 these cells6.  
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42 Taking inspiration from the natural pathway of MRV transcytosis across M cells (Fig. 1a), we 
43 hypothesized that artificial virus-like nanocarriers (AVNs), comprised of T1L σ1 conjugated gold 
44 nanocages would be able to effectively transcytosis through M cells. Hence, these AVNs can serve as 
45 effective transport vehicles for oral vaccines. AVN construction required purification of 1, preparation 
46 of gold nanocages, and linkage of 1 to the nanocage surface in an appropriate conformation where the 
47 head domain (C-terminal portion)7 of σ1 can interact with α2-3 sialic acid located on the M cell apical 
48 surface6. 
49 With the nanocarriers being surface-functionalized with T1L σ1, conventional 2-D spherical 
50 nanoparticles were not good candidates as the outer surface would no longer be available for payload 
51 loading. In this study, we chose gold nanocages (i.e., hollow nanocubes) as our base for nanocarrier 
52 development mainly due to their easiness to fabricate and their internal loading capacity. The 
53 nanocages had holes to allow loading/unloading of payloads. Coating could be added to cover the outer 
54 surface to further protect the payloads sealed inside for oral vaccine to survive the harsh gastric 
55 environment.
56 To test our hypothesis, a simple and effective testing platform was developed using M cell containing 
57 intestinal monolayers derived from mouse intestinal organoids in which M cell differentiation was 
58 induced using recombinant RANK ligand (RankL)8. Compared with a monolayer of Caco-2 cells, the 
59 organoid monolayer contains various epithelial cell types, such as goblet cells, enteroendocrine cells, 
60 enterocytes and Paneth cells9. The development of an ex vivo intestinal mucosal system composed of a 
61 continuously expanding, self-organizing structure, reminiscent of normal intestinal epithelium, provides 
62 an alternative that bridges the gap between cell lines and in vivo animal models for the study of oral 
63 vaccines. Based on previous studies10, the organoid generated monolayers are polarized as evidenced by 
64 the fact that they maintain apical and basally oriented membranes, which is a critical component of our 
65 model as MRV adheres to the apical membrane of M cells in vivo11. Additionally, from previous studies, 
66 M cells can be induced in both 2D and 3D organoid systems12. Our experimental setup used transwell 
67 plates containing an M cell embedded organoid monolayer mimicking an intestinal mucosal layer on the 
68 top inserts, with the bottom compartment mimicking a MALT site (Fig. 1b). Using this system, we 
69 examined the capacity of AVNs to exploit M cell-mediated uptake through interaction of 1-conjugated 
70 AVNs with 2-3 sialic acids followed by transcytosis through M cells. 
71 Fig. 1 Scheme: T1L σ1 functionalized Gold nanocage explore M cell pathway
72
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73 a, Model of MRV infection of enteric tissue. b, Experimental design to test the transport of σ1 
74 functionalized AVNs through M cells incorporated to intestinal organoid monolayers. 
75 Results and discussion
76 Artificial Virus-like Nanocarriers: Gold nanocages and MRV σ1
77 Gold nanoparticles are widely used in the drug/vaccine delivery field13,14,15 ,16,17,18. Gold nanocages (GNC) 
78 are 3D structures with a hollowed interior which allows a substantially increased loading capacity for 
79 payload (e.g., drugs or immunogens) when compared with 2D delivery vehicles. GNC were produced 
80 using a two-step galvanic replacement reaction15,16. In the first step, silver nanocubes were fabricated as 
81 sacrifice templates, and in the second step, a galvanic replacement reaction was utilized to replace silver 
82 with gold. 3D hollowed gold nanocages were obtained from this reaction with an average size of 40 nm 
83 (Fig.  2a). GNC utilized throughout our study had an absorption peak of around 760 nm (Fig. 2b). MRV 1 
84 was harvested from purified MRV as previously described19,20,21. Presence of σ1 protein is confirmed by 
85 Western blot using the T1L virion antisera which recognizes 1 along with other capsid proteins. In Fig. 
86 2c, our Western blot analysis revealed one band at 50 kDa representing σ1 protein (right lane). No band 
87 was detected in filtered suspension (middle) indicating there was no unconjugated σ1 protein present, 
88 while in the post-purification pellet (left), all MRV structural proteins were revealed. EDC/NHS mediated 
89 conjugation was utilized to link σ1 proteins onto GNC22,23 to produce AVNs.  Conjugation success was 
90 confirmed by incubation of AVNs as well as GNC without 1 conjugation (i.e., control) with gold 
91 nanospheres (GNS) conjugated with a 1 specific monoclonal antibody (5C6). While the control 
92 maintained absorption peaks representing free-floating GNC (760 nm) and GNS (550 nm), the (GNC-1) 
93 + (GNS-5C6) group showed no absorption indicating aggregation via σ1-5C6 crosslinking and confirming 
94 1 conjugation to GNC.
95
96 Fig. 2: MRV σ1 functionalization of GNC. 
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97
98 a, TEM (Transmission Electron Microscopy) image of GNC showing 40 nm average size. b, UV 
99 (Ultraviolet) absorption of GNC shows characteristic peak at 760 nm. c, Western blot for pellet after last 
100 centrifuge, control group and T1L σ1 protein (50 kDa). Following purification, T1L σ1 protein. T1L 1 
101 protein was concentrated using a 30 kDa filter (right). Filtrated solution (middle) and pellet (left) serves 
102 as the control. d, GNC conjugated with MRV 1 protein (GNC+1) or (GNC) alone, and GNS conjugated 
103 with 1 monoclonal antibody 5C6 (GNS+5C6) or not (GNS) were incubated together and absorption was 
104 measured to identify aggregation. 
105 Microfold cell (M cell) incorporated intestinal monolayer preparation 
106 Intestinal organoids are 3-dimensional structured epithelium that are derived from small intestinal stem 
107 cells9. Stem cells were isolated from the small intestine of C3H/HeN conventional mice and mixed with 
108 Matrigel containing growth medium supplemented with growth factors including R-spondin 1, EGF, and 
109 Noggin24. Previous studies25,26,27,28,29 have demonstrated that adding RankL to the organoids culture 
110 medium induced the M cells appearance. The expression of M cells were confirmed by expressing M cell 
111 surface protein glycoprotein 2 (GP2) and  M-cell-specific molecules annexin V (Anxa5)5 on organoids.  
112 Additionally, biotin-conjugated lectin UEA-1 (UEA-1) binds specifically to sites of α-1,2 fucosylation on 
113 the surfaces of M cells30. Hence, UEA-I and GP-2 are both specific markers for RankL induced M cells. 
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114 While UEA-1 binds specifically to apical sites of α-1,2 fucosylation on the surfaces of M cells in the 
115 epithelial layer, GP-2 binds specifically to basal sites surface of M cells in the epithelial layer. As shown in 
116 fig.3a, the fluorescent signals for GP-2 and UEA-1 indicated the distribution of the induced M-cells at 
117 both apical sites and basal sites. 
118
119 Based on these observations, M cells were induced in 3D structured organoids by 3-day incubation in 
120 the presence of RankL. Similar to prior studies25,26,27,28,29, we found lectin UEA-I binding (shown as red) 
121 and M cell marker GP2 expressed (shown as green) in organoids treated with RankL, but not in 
122 untreated organoids (Fig. 3a). For further verification, gene expression analysis was performed using RT-
123 qPCR and primers specific for Anxa5 and GP2. Consistent with the expression of M cell markers seen by 
124 immunofluorescence, organoids treated with RankL significantly upregulated the expression of both 
125 Anxa5 and GP2 relative to untreated cells (Fig. 3b).  Finally, Western blot was performed using 
126 antibodies specific for annexin V in which RankL induced organoids showed a specific band with the 
127 correct molecular weight that was not present in the untreated organoids (Fig. 3c). 
128
129 Taken together, these findings strongly suggest that a 3-day incubation with RankL resulted in the 
130 induction of M cells within the organoids. While intact 3D organoids are useful for many experiments, 
131 our assay required a monolayer, and it has been demonstrated previously that organoids can be 
132 disrupted and plated on tissue culture plates to form a monolayer10. In order to achieve this, we treated 
133 organoids for 2 days with RankL, disrupted and re-plated the cells as a monolayer in the presence of 
134 RankL for an additional 24 hours on the top compartment of a transwell tissue culture inserts (Fig 1b) for 
135 further experiments. As shown in Fig. 3d, organoid monolayers positively stained for GP2, which was 
136 absent in control samples not receiving RankL, indicating that M cells were present in the monolayer 
137 system. Additionally, E-Cadherin staining was performed to verify the presence of tight junctions within 
138 the monolayers in both control and RankL-treated groups (Fig. 3d). The morphology of the monolayers is 
139 further demonstrated by bright field images in supplemental Fig. 1. 
140
141 Fig. 3: Detection of Microfold cells in 3D mouse organoids and 2D organoid-
142 derived monolayers.
143
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144 a, Immunofluorescence images of untreated and 3 day RankL-treated 3D organoids with antibodies 
145 against M cell marker proteins GP2 (green) and UEA-I lectin (red). Nuclei are stained with DAPI (blue). b, 
146 RT-qPCR analysis for expression of Anxa5- and GP2-specific mRNA isolated from untreated and RankL-
147 treated organoids. c, Western blot analysis of cell lysates from untreated and RankL-treated organoids 
148 using antibodies against Anxa5. d, Immunofluorescence images of organoid monolayers stained with 
149 antibodies against GP2 (green) and E-Cadherin (red). Nuclei are stained with DAPI (blue). The boxed 
150 region in the merged image was amplified and is shown in the inset.
151 Transport behavior of Mammalian orthoreovirus through organoid Monolayers
152 As proof of concept that our organoid monolayer recapitulates MRV transcytosis through M cells, 
153 experiments were conducted to measure MRV transport through intestinal organoid monolayers with or 
154 without M cells in the transwell system (Fig.1b). Purified MRV was added to untreated or RankL-treated 
155 organoid monolayers plated on the top compartment of transwell. At 2, 4, 6, and 12 hour, culture 
156 medium from the bottom compartment was collected and used for virus plaque assay to examine the 
157 amount of virus that passed through the monolayer as a measure of MRV transcytosis through M cells. 
158 At each time point, there was an increase in MRV transport into the bottom transwell in RankL-treated 
159 versus control monolayers, with two of the time points showing statistically significant differences. 
160 Moreover, when measuring the transport total of MRV across the organoid monolayer, the presence of 
161 RankL significantly increased the speed at which the virus moved into the bottom compartment (Fig. 
162 4b). (supplementary Note 1). To confirm M cell presence and MRV infection in these monolayers, the 4 
163 h time point was immunostained with antibodies against GP2 and MRV (Fig. 4c). A noticeable overlap of 
164 GP2 and MRV staining can be observed in the RankL treated samples, further supporting MRV binding 
165 and transport through M cells in this system. Taken together, these data corroborate previously 
166 published data that MRV exploits the M cell pathway for transport into the MALT and support our 
167 hypothesis that this system can be used for measuring M cell dependent transport of AVN across the gut 
168 mucosa. 
169
170
171
172
173
174 Fig. 4 MRV Transport behavior on Organoid Monolayers
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175
176 a, PFU of MRV transport through M cell induced monolayer, monolayers with M cell induction (control) 
177 and 1% Matrigel without monolayers for 2, 4, 6 and 12 hours. p values were calculated and indicated on 
178 top of the bar line.  b, MRV transport total at 2, 4, 6, and 12 hours, on monolayers with and without M 
179 cell induction. c, Immunofluorescence images of MRV-infected monolayers treated or untreated 
180 (control) with RankL using antibodies against MRV and GP2. 
181 Transport of AVNs through organoid Monolayer
182 Following production and validation of AVNs and organoid monolayers, we tested our hypothesis that 
183 AVNs could be transported across the gut monolayer via 1 binding and transcytosis through M cells.  
184 Using the small molecule dye Rhodamine 6G (R6G) as payload within the GNCs and AVNs, monolayers 
185 with and without M cells were overlaid with R6G (baseline for transport), R6G loaded GNCs, and R6G 
186 loaded AVNs. At 0, 0.5, 1, 2, 3, 4, 8, 12, 24, 36, and 48 hour post-treatment, samples were removed from 
187 the lower compartment of transwells and fluorescence was measured (Fig. 5a). These experiments 
188 demonstrated that AVNs display the highest transport across the organoid monolayer containing M cells 
189 among all four experimental groups. Moreover, while there are no differences in total transport 
190 between monolayers with and without M cells in the R6G and GNC groups, the addition of 1 to the 
191 AVN group resulted in an increase in transport in the presence of M cells, strongly suggesting that the 
192 AVN group is using the 1:M cell-mediated transcytosis pathway. When examining the first 8 hours, the 
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193 transcytosis of AVNs across M cell containing monolayers is distinguished from the other three 
194 experimental groups, in that the transport total was higher than for AVNs across monolayers without M 
195 cells (Fig. 5b). As for GNCs, regardless of whether M cells were presented in the monolayers, the 
196 transport total were significantly lower than that of the AVNs. (Supplementary Note 2). At early time 
197 points (hour 1 to 4), AVNs possessed a higher transport total than free R6G (Supplementary Fig. 2) In all 
198 four groups, some R6G payload diffused out of the nanocages throughout the experiments, and were 
199 detected in the bottom compartment. We suggest that R6G is released from the nanocages in the top 
200 compartment and transported through the monolayers as small molecules do. When examining the UV 
201 spectra of samples collected from the bottom compartment after 48 hour, only the AVNs on monolayers 
202 with M cells contain a specific Gold nanocage absorption peak (~760 nm) in the bottom solution (Fig. 
203 5c). This strongly indicates that only the AVNs can transport through the monolayer, and further only in 
204 monolayers with M cell presence, most likely via 1-mediated transcytosis through the α2-3 sialic acid 
205 pathway. Gold nanocages otherwise cannot go through the intestinal monolayer, regardless of whether 
206 they are T1L σ1 functionalized or not. Therefore, both of the two factors, T1L σ1 and M cells, are needed 
207 for the transport of AVNs through intestinal organoid monolayers. We performed a quantitative 
208 assessment of how many payloads (R6G) inside AVNs that transported through monolayer. 
209 (Supplementary Note 3). The overall transport of payloads in AVNs was 20% at 48 hour (Fig. 5d). These 
210 results strongly suggest that AVNs could be quite effective in transporting payloads through M cells in 
211 the gut mucosa, and potentially serve as promising oral vaccine carriers.
212  Fig.  5: Transport behavior on monolayer platform
213
214
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215 a, Payload (R6G) in different vaccine delivery vehicle (AVN, GNC) transport across intestinal monolayers, 
216 with and without M cell induction over time.  b, First 8 hour in boxed region of Fig 5.a, c, UV absorption 
217 of each sample at 48 hour. d, AVN transport total through intestinal monolayers with M cells 
218 incorporated. 
219 Conclusion
220 To summarize, artificial virus-like nanocarriers (AVNs) comprised of gold nanocages functionalized with 
221 MRV receptor binding protein σ1 were created that could effectively utilize M cells for transport across 
222 intestinal monolayers, mimicking the MRV transport pathway. Analysis revealed that both MRV σ1 
223 functionalization of the AVNs and M cell presence in the monolayer were needed for demonstrable 
224 transport across the monolayer. The transport was reasonably efficient with ~20 % of total AVNs 
225 transported across the intestinal monolayer within 48 hour. This data suggests that AVNs, carrying an 
226 antigen or drug payload, could be used for oral delivery across the gastrointestinal mucosa into mucosal 
227 associated lymphoid sites (e.g., Peyer’s patches) for enhanced vaccine effectiveness.  
228 Experimental 
229 Gold nanocage fabrication 
230 Ethylene glycol (EG) (Sigma-Aldrich) (6 ml) was heated in 160 ˚C oil bath for 1 hour. Polyvinylpyrrolidone 
231 (PVP) (Sigma-Aldrich) (0.07 g) was added into 3.5 ml EG solution, and mixed well. AgNO3 (Sigma-Aldrich) 
232 (0.12 g) was added into 2.5 mg EG solution and mixed well. Well mixed 3 mM NaSO4 (Acros) EG solution 
233 was made by adding 70 ul of the sodium sulfide solution to EG solution in oil bath. 10 minutes later, 1.5 
234 ml PVP solution and 0.5 ml Silver Nitrate solution were added into the reaction system and reacted for 
235 10-15 mins. At the end of this incubation, 6 ml of acetone were added to cool down the reaction mix. 
236 The silver nanocube solution obtained from the above steps was centrifuged at 1,300 rpm for 30 min. 
237 The supernatant was removed, and 1 ml of deionized water was added. The nanocubes were then re-
238 suspended in DI water in a sonicator for at least 1 hour. Then the nanocubes were washed twice, 
239 collected by centrifugation at 9,000 rpm, before re-dispersed de-ionized water. 
240 PVP (20 mg) was dissolved in 20 ml of deionized water. The PVP solution was then heated to 245 ˚C and 
241 stirred at 220 rpm. Once the PVP solution started to boil, 200 µL of Silver nanocubes were added into it. 
242 The combined solution was stirred and heated for an additional 10 minutes. 10 µL of HAuCl4 (Sigma-
243 Aldrich) was then added in 2-minute increments until desired concentration was attained (determined 
244 by solution color). Further verification of the concentration was done using UV-Vis spectrometry. The 
245 solution was then boiled down to 1 ml to concentrate the gold nanocages and NaCl was added in excess 
246 into solution until saturation17,18.  The GNC solution was centrifuged for 30 minutes at 2000 g to form a 
247 pellet. The supernatant was removed, and 1 mL of distilled water was added. The solution was sonicated 
248 for 1hour to re-disperse the pellet back into a stable solution. Then the nanocages were centrifuged at 
249 9000 g for 10 minutes and re-dispersed in in sonicator for 1hour. This last step was repeated one more 
250 time. The washed gold nanocages were stored at 4˚C.
251
252 T1L σ1 isolation and purification
253 L929 mouse fibroblast cells were maintained in Joklik modified minimum essential medium (Sigma-
254 Aldrich) supplemented with 2 % fetal bovine serum, 2 % bovine calf serum (HyClone), 2 mM L-glutamine 
255 (Mediatech), and penicillin (100 IU/ml)–streptomycin (100 μg/ml) solution. MRV strain type 1 Lang (T1L) 
256 was propagated in spinner adapted L929 cells, the cells were harvested by centrifugation at 3000 x g for 
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257 10 min, resuspended in HO buffer (250 mM NaCl, 10 mM Tris, pH 7.4), and frozen at -80oC 19. Virus was 
258 purified as described 19 with the substitution of Vertrel® XF (DuPont) in place of Freon 21. Purified MRV 
259 was then digested with chymotrypsin and purified to produced ISVPs 20, and then heated to 52 oC for 
260 30 min to release σ1 19. The ISVPs were pelleted at 35,000 rpm and the supernatant containing free σ1 
261 was concentrated in a Centricon-30 microconcentration unit (Amicon Corp.) as described19.
262 Gold nanocage functionalization 
263 GNC functionalization was achieved using (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
264 hydrochloride) (EDC) (Thermo scientific) /N-hydroxysulfosuccinimide (NHS) (Sigma-Aldrich) procedure. 
265 4-Aminothiophenol was linked onto GNC by shaking overnight. The solution was centrifuged at 9,000 g 
266 for 10 minutes, then add DI-water was added, and GNC were re-dispersed in sonicator for 30 minutes to 
267 remove excess 4-Aminothiophenol.  Freshly made EDS/NHS solution was added to GNC for 30 mins at 
268 room temperature. MRV T1L σ1 protein aqueous solution was added and incubated 2 hours at room 
269 temperature, and the reaction was stopped with 1 ml PBS with Tween-20 (PBST) to stop reaction. 
270 Finally, the solution was centrifuged at 6,500 x g for 30 mins, the supernatant was removed, and 2 ml of 
271 deionized water were added to re-disperse the nanocages 22,23.
272 High-resolution immunofluorescence microscopy
273 Organoids were grown in 4-well chamber slides and were fixed with 4% paraformaldehyde for 1 hour at 
274 room temperature. Sections were permeabilized with 0.5 % TritonX buffer (250 µL Triton-X100 in 50 mL 
275 PBS) for 30 minutes, after PBS washes for 3 times, 1% PBSA was used for making primary antibodies’ 
276 solution then stained overnight at 4 °C. Then, at day 2, secondary antibodies were added and incubated 
277 at room temperature for 2 hours. After 3 times PBS washes, 4’, 6-Diamidino-2-phenylindole (DAPI) (EMD 
278 Millipore) was used to stain nuclei and stick cells under cover slips. After drying the slides for 1 day in 
279 dark, slides were ready to use for observation under microscope. Fluorescence staining images were 
280 acquired with the Olympus®IX81 laser scanning confocal microscope using a 100X oil-immersion 
281 objective. 
282 For staining with UEA-1, Lectin Ulex europaeus(biotinylated UEA-1, Sigma) and rabbit anti-biotin 
283 (Rockland) were used with a suggested concentration of 10 µg/ml. For secondary antibody, goat anti-
284 rabbit antibody– Texas Red X (Invitrogen) were used at a 1:250 dilution. For staining GP2, primary 
285 antibody Rat anti-GP2 (MBL International Corporation) was used with a concentration of 2.5 µg/ml, 
286 secondary antibody goat anti-rat FITC (ThermoFisher) was used at a 1:250 dilution. For staining E-
287 Cadherin, primary antibody rabbit anti-E-cadherin (Invitrogen) was used at a 1:250 dilution, followed 
288 with a secondary antibody Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 594) (Abcam) at a 1:250 dilution.  
289 For MRV staining, Rabbit T1L anti-virion antibody, Mouse anti-σ3 5C3, Mouse anti-σ3 10C1 and Mouse 
290 anti-µ1 4A3 were used at a 1:250 dilution31,32. The following day, secondary antibody donkey anti-mouse 
291 Alexa Fluor® 594 (Invitrogen) and Donkey Anti-Rabbit IgG H&L (Alexa Fluor® 594) at a 1:250 dilution was 
292 used.  
293 Quantitative RT-PCR for verifying microfold cells development
294 Matrigel was removed from organoids by treating them with 1000 μl of Cell Recovery Solution (Corning 
295 Life Sciences) with shaking for 1 h at 4°C, followed by two PBS washes. RNA was extracted by using 
296 RNeasy Mini Kit (Qiagen) following the manufacturer’s procedure. Concentration and purity of the 
297 extracted RNA were checked by NanoDrop spectrophotometer. Three primer pairs were purchased from 
298 the DNA facility, Iowa State University, Ames, IA: Anxa5 (F: 5’-ATCCTGAACCTGTTGACATCCC-3’; R: 5’-
299 AGTCGTGAGGGCTTCATCATA-3’), GP2 (F:5’-CTGCTACCTCGAAGGGGACT-3’; R: 5’-
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300 CATTGCCAGAGGGAAGAACT-3’) and a primer for housekeeping gene Gapdh (F: 5’-
301 TTCACCACCATGGAGAAGGC-3’; R: 5’-GGCATGGACTGTGGTCATGA-3’). Power SYBR™ Green RNA-to-CT™ 
302 1-Step Kit was used. Gene expression levels were normalized against that of the housekeeping genes.
303 Western blot for verifying presence of M cell related proteins and σ1 protein
304 Matrigel was removed from organoids by treating them with 1000 μl of Cell Recovery Solution (Corning 
305 Life Sciences) with shaking for 1 h at 4°C, followed by PBS washes. For 1 identification, MRV was 
306 collected in protein loading buffer. Cells or MRV was denatured by heating 5 to 10 mins at 100 °C. 
307 Proteins were separated on a 4% Tris-HCl SDS-PAGE gel. Gels were transferred to nitrocellulose 
308 membrane and Western blotting was performed with Rabbit Anti-Anxa5 antibody (Abcam) at a dilution 
309 of 1:500; anti--tubulin monoclonal mouse antibody (ThermoFisher Scientific) at a dilution of 1:1000. 
310 For σ1 protein, Western blotting was performed with Rabbit T1L virion antibody at a dilution of 1:1000. 
311 Blots were washed 3X in Tris-buffered saline (20 mM Tris, 137 mM NaCl [pH 7.6]) with 0.25% Tween 20 
312 (TBST) buffer, and then incubated with secondary goat anti-rabbit IgG (BioRad, 170-6518) at a dilution of 
313 1:2500. After three additional washes, membranes were subjected to PhosphaGLO AP (SeraCare) to 
314 image detected proteins3.   
315  
316 Minigut monolayer development
317 Murine organoids were cultured for 3 days using well established methods9. At day 3, for M cell 
318 differentiation, 200 ng/ml RankL was added and incubated for an additional 2 days. Resulting 3D 
319 structured organoids were disrupted and pipetted into buffer containing 0.5 mM EDTA, and centrifuged 
320 at 200 x g at 4 °C for 5 mins. 500 μl of 0.05 % trypsin/0.5 mM EDTA was added to the pellet for 
321 dissociation. After incubating for 4 mins at 37 °C, 1 ml DMEM/F12 with 10% FBS was added to inactivate 
322 trypsin. The cell suspension was filtered through a 40 μm cell strainer and filtered cells were dropped on 
323 solidified 1% Matrigel coated wells to form a monolayer. 100 μl of culture medium was added on top of 
324 the cell layer, and 500 μl of culture medium were added to the bottom.  Monolayers were used for 
325 experiments after 24 hours. For M cell development, RankL 200 ng/ml was added in both top and 
326 bottom compartments. 
327
328 Transport of Mammalian orthoreovirus across intestinal monolayer in transwell model 
329 system
330 Purified virus was serially diluted and subjected to a modified plaque assay analysis19 ,33. In brief L929 
331 cells were seeded at 1.2 x106 cells/mL (or per well) in 6-well plates and upon monolayer formation, the 
332 medium was removed and virus diluted in phosphate-buffered saline (PBS) (137 mM NaCl, 3 mM KCl, 8 
333 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) with 2 mM MgCl2. Virus was incubated on monolayers for 1 h at 
334 room temperature, then bottom solution was collected at 2 hour, 4 hour, 6 hour, and 12 hour after the 
335 addition of virus to the top of the transwell system. Then, 10 µl of the culture medium from the bottom 
336 chamber was collected and overlaid with 2 ml of 1 % Bacto Agar (Becton Dickinson), 1x Medium 199 
337 (Life Technologies) supplemented with 2.2 g/L sodium bicarbonate (Fisher Scientific), and 12 µg/ml 
338 trypsin (Worthington Biochemical) solution.  Dilutions were made for 10-3, 10-4,10-5, and 10-6 by using the 
339 previously made solution. Once the overlay solidified, the 6-well plates were placed at 37oC and 5% CO2 
340 and plaques were counted 2 days later. The means and standard deviations were determined from two 
341 biological replicates done in triplicate.
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342 Transport of AVNs across intestinal monolayer in transwell model system
343 Rhodamine 6G (Sigma-Aldrich) (15 µl, 10 mM) was incubated with 1.5 ml of OD=3.0 GNCs and AVNs 
344 overnight by shaking at 4 °C to allow loading of R6G into the nanocages via diffusion. R6G loaded 
345 nanocages were collected by centrifugation at 9,000 x g. Supernatants were removed, and the 
346 nanocages were re-dispersed in 1 ml of deionized water under sonication. Initial R6G fluorescence 
347 intensities were recorded, and 150 µl of R6G-loaded AVNs or nanocages were added to each transwell. 
348 At 0, 0.5, 1, 2, 3, 4, 8, 12, 24, 36, and 48 hour, 50 l was collected from the lower compartment of the 
349 transwell setup, and R6G fluorescence intensities were recorded. Each experiment was conducted in 
350 triplicate.
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